FET-PET for Evaluation of Response of Recurrent GBM to Avastin
Status:
Completed
Trial end date:
2015-09-13
Target enrollment:
Participant gender:
Summary
Hypothesis: The central hypothesis underlying the proposed research study is that FET-PET
will predict durable benefit in patients receiving anti-angiogenic benefit for presumed
recurrent GBM (i.e. progression-free survival and overall survival). We have defined one
primary specific aim, for which we expect to obtain definitive results, and two secondary
aims, under which we plan to generate preliminary data to support a future, larger project.